Key Definitions
- Ferritin: Iron storage protein; levels <30 ng/mL indicate depleted stores even with normal hemoglobin. Cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.
- Tyrosine hydroxylase (TH): Enzyme converting L-tyrosine to L-DOPA; requires iron as cofactor. Rate-limiting step in catecholamine (dopamine, norepinephrine) production.
- DAT (Dopamine transporter): Membrane protein that clears dopamine from the synapse. Zinc blocks DAT at an extracellular site, increasing synaptic dopamine.
- SCFA (Short-chain fatty acids): Bacterial metabolites (butyrate, propionate, acetate) produced from fiber fermentation; influence brain function via gut-brain axis.
- Non-responder: Individual showing <10% improvement despite adequate supplementation; may have genetic variants affecting nutrient metabolism or already-optimal baseline levels.
- Adjunctive therapy: Supplement used alongside (not instead of) standard ADHD treatment (medication, behavioral therapy).
Key Findings
- 84% of ADHD children have ferritin <30 ng/mL versus normal controls at 44 ng/mL; ferritin inversely correlates with ADHD severity (r = −0.34) (Konofal et al., 2004)
- Vitamin D is 6.55 ng/mL lower in ADHD vs. controls (P < .001), with OR 1.97 for ADHD in deficient individuals (2025 meta-analysis)
- Zinc supplementation reduces ADHD total scores (SMD: −0.62, P = .04) across 6 RCTs with 489 children (Talebi et al., 2022)
- Omega-3 requires ≥4 months for significant effect (SMD: −0.35, P = .007); shorter durations show no benefit (Chang et al., 2023)
- Magnesium L-threonate is the only form with ADHD-specific trial data; 47% response rate in pilot study (Surman et al., 2021)
- L-tyrosine develops tolerance within 6 weeks — all 8 initial responders lost benefit (Reimherr et al., 1987)
- Czech-specific: Only 19.2% of Czech youth have sufficient vitamin D (≥75 nmol/L); 51.5% never supplement (Holmannová et al., 2025)
Methodology Note
This protocol synthesizes findings from 28 primary sources including meta-analyses on iron (Tseng et al., 2018), vitamin D (2025 meta-analysis), zinc (Talebi et al., 2022), and omega-3 (Chang et al., 2023), alongside RCTs on specific interventions. We prioritized supplements with established mechanisms in dopamine synthesis and meta-analytic evidence. L-tyrosine was included specifically to document lack of evidence. Full methodology: /methodology
Table of Contents
- The Hierarchy
- Tier 1: Screen First (Iron, Vitamin D)
- Tier 2: Evidence-Based Adjuncts (Zinc, Magnesium)
- Tier 3: Conditional (Omega-3)
- What Doesn’t Work
- Protocol Summary
- Comparison Tables
- Limitations & Caveats
- Related Topics
- Sources
The Evidence Hierarchy {#hierarchy}
Not all ADHD supplements are equal. As of April 2026, evidence sorts into clear tiers:
| Tier | Action | Supplements |
|---|---|---|
| 1: Screen First | Test → supplement if deficient | Iron (ferritin), Vitamin D |
| 2: Evidence-Based Adjunct | Consider alongside medication | Zinc, Magnesium |
| 3: Conditional | May help specific subgroups | Omega-3 (≥4 months only) |
| 4: No Evidence | Skip these | L-tyrosine, creatine (for ADHD specifically) |
The critical insight: ADHD supplement response depends on baseline deficiency status. Supplementing someone with adequate ferritin is unlikely to help; supplementing someone at 18 ng/mL may be transformative.
Tier 1: Screen First {#tier-1}
Iron (Ferritin): The Most Actionable Biomarker
Why ferritin matters for ADHD:
Iron is a required cofactor for tyrosine hydroxylase — the enzyme that converts tyrosine to L-DOPA, the rate-limiting step in dopamine synthesis. Low iron = impaired dopamine production at the enzymatic level.
The evidence is striking:
Konofal et al. (2004, Archives of Pediatrics & Adolescent Medicine) found:
- Mean ferritin in ADHD children: 23 ng/mL
- Mean ferritin in controls: 44 ng/mL (P < .001)
- 84% of ADHD children below 30 ng/mL
- Ferritin inversely correlated with ADHD severity (r = −0.34)
Tseng et al. (2018, Scientific Reports) meta-analyzed 17 articles:
- ADHD individuals have significantly lower ferritin (Hedges’ g = −0.246)
- Iron-deficient ADHD shows dramatically higher symptom severity (Hedges’ g = 0.888)
Target levels:
| Level | Interpretation |
|---|---|
| <30 ng/mL | Depleted stores — supplement indicated |
| 30–50 ng/mL | Suboptimal for brain function — consider supplementation |
| >50 ng/mL | Adequate — no supplementation needed |
| >100 ng/mL | Upper limit for supplementation |
Protocol if deficient:
- Form: Ferrous bisglycinate (better tolerated) or ferrous sulfate (cheaper, more GI effects)
- Dose: 18–65 mg elemental iron/day depending on severity
- Timing: Away from calcium, coffee, tea; with vitamin C to enhance absorption
- Retest: After 3 months
⚠ Important: Iron overload is harmful. Do NOT supplement without testing ferritin first. Normal hemoglobin does not rule out low ferritin.
Vitamin D: Strong Association, Czech Epidemic
The mechanism:
Vitamin D regulates expression of tyrosine hydroxylase (Cui et al., 2015, Neuroscience), directly linking it to dopamine synthesis. It also modulates over 200 genes involved in brain development and neurotransmission.
The evidence:
A 2025 meta-analysis in Middle East Current Psychiatry found:
- ADHD children have −6.55 ng/mL lower serum vitamin D (P < .001)
- OR 1.97 for ADHD in vitamin D deficient individuals
Czech-specific crisis:
Holmannová et al. (2025, European Journal of Clinical Nutrition) studied 119,925 Czechs:
- Only 19.2% of 6–15 year-olds have sufficient vitamin D (≥75 nmol/L)
- Only 22.1% of 16–30 year-olds sufficient
- 51.5% never supplement
- >95% have inadequate dietary intake (Czech TDS, 2018)
This means the vast majority of Czech ADHD patients are likely vitamin D deficient.
Protocol:
| Status | Action |
|---|---|
| <30 nmol/L (deficient) | 4000–6000 IU/day for 8–12 weeks, then retest |
| 30–75 nmol/L (insufficient) | 2000–4000 IU/day maintenance |
| >75 nmol/L (sufficient) | 1000–2000 IU/day maintenance |
Form: D3 (cholecalciferol) with fatty meal for absorption. D2 is less effective.
Tier 2: Evidence-Based Adjuncts {#tier-2}
Zinc: DAT Modulator with Meta-Analytic Support
The mechanism:
Zinc is a non-competitive blocker of the dopamine transporter (DAT) at a high-affinity extracellular binding site (His-193, His-375, Glu-396). By inhibiting DAT, zinc increases synaptic dopamine availability — mechanistically similar to stimulant medications, though weaker (Lepping & Huber, 2010, CNS Neuroscience & Therapeutics).
The evidence:
Talebi et al. (2022, Critical Reviews in Food Science and Nutrition) meta-analyzed 6 RCTs (489 children):
- Zinc supplementation significantly reduced ADHD total scores (SMD: −0.62, P = .04)
- Individual subscales (hyperactivity, inattention) not individually significant
- Heterogeneity high — response varies
Bilici et al. (2004) tested zinc sulfate 150 mg/day (~34 mg elemental) in 400 children:
- Significant improvement versus placebo at 12 weeks
However: Skalny et al. (2021, Scientific Reports: 22 studies) found no statistically significant difference in serum zinc between ADHD and controls — suggesting the benefit may be pharmacological (DAT modulation) rather than deficiency correction.
Protocol:
- Dose: 15–30 mg elemental zinc/day
- Form: Zinc picolinate or zinc bisglycinate (better absorbed than oxide)
- Timing: Away from copper, iron, calcium supplements (competition)
- Duration: Minimum 12 weeks to assess response
- Caution: Long-term high-dose zinc depletes copper; consider cycling or taking with copper (2 mg Cu per 30 mg Zn)
Magnesium: Lower in ADHD, Limited Trial Data
The mechanism:
Magnesium is involved in over 300 enzymatic processes including neurotransmitter release and NMDA receptor function. Hypomagnesemia is associated with hyperexcitability.
The evidence for deficiency:
Huang et al. (2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry) meta-analyzed 8 studies:
- Serum magnesium Hedges’ g = −0.733 lower in ADHD children
- This is a large effect size for a biomarker
The evidence for supplementation is weaker:
Magnesium L-threonate is the only form with ADHD-specific trial data:
- Surman et al. (2021, Journal of Dietary Supplements): open-label pilot, 15 adults
- 47% met response criteria
- But: unblinded, n=15, industry-funded (Neurocentria Inc.)
L-threonate uniquely crosses the blood-brain barrier and increases brain magnesium in hippocampus and prefrontal cortex (preclinical evidence). Other forms may not achieve brain penetration.
Protocol:
- Preferred form: Magnesium L-threonate (1–2g/day providing ~144 mg elemental Mg)
- Alternative: Magnesium glycinate/bisglycinate (200–400 mg elemental) — calming, good for sleep issues
- Avoid: Magnesium oxide (~4% absorption, primarily laxative effect)
- Timing: Evening (promotes sleep; many ADHD patients have delayed sleep phase)
Tier 3: Conditional {#tier-3}
Omega-3: Requires Long Duration, Small Effect
The mechanism:
EPA and DHA are incorporated into neuronal membranes, affecting fluidity and receptor function. EPA has anti-inflammatory effects potentially relevant to neuroinflammatory ADHD subtype.
The evidence is nuanced:
Chang et al. (2023, Journal of Clinical Psychiatry: 22 RCTs, 1,789 participants) found:
- Overall: omega-3 did NOT significantly improve ADHD symptoms (SMD: −0.16, P = .07)
- BUT: ≥4 month treatment showed significant benefit (SMD: −0.35, P = .007)
- Neither high EPA dosage nor high EPA:DHA ratio improved outcomes
This means:
- Short-term trials (the majority) show no effect
- Only sustained supplementation produces measurable improvement
- The effect size is small even when significant
A 2025 systematic review concluded: “Omega-3 may not have a significant effect on ADHD symptoms to recommend its use.”
Protocol (if choosing to try):
- Dose: 1–2g combined EPA+DHA/day
- Form: Triglyceride form > ethyl esters for absorption
- Duration: Minimum 4 months — shorter trials are uninformative
- Expectation: Small effect at best; not a substitute for first-line treatment
What Doesn’t Work {#doesnt-work}
L-Tyrosine: Tolerance Develops, No Benefit
L-tyrosine is heavily marketed for ADHD with the rationale that it’s a dopamine precursor — “feed the pathway.”
The evidence says otherwise:
Reimherr et al. (1987, American Journal of Psychiatry) — the only ADHD-specific trial:
- 12 adults, L-tyrosine 50–150 mg/kg/day
- 8 showed initial improvement
- All 8 developed tolerance within 6 weeks — benefit completely disappeared
Nemzer et al. (1986) — pediatric double-blind study:
- Tyrosine not different from placebo
Why it doesn’t work:
Tyrosine hydroxylase (the enzyme converting tyrosine to L-DOPA) is regulated by end-product inhibition. Simply increasing substrate (tyrosine) does not proportionally increase dopamine synthesis — the enzyme downregulates.
Verdict: No high-quality evidence supports L-tyrosine for ADHD. Claims on supplement websites are not evidence-based. Save your money.
Creatine: Works for Cognition, Not ADHD-Specific
Creatine has solid evidence for cognitive enhancement in specific populations (see our creatine protocol), but no dedicated ADHD RCTs exist.
Wu et al. (2024, Frontiers in Nutrition: 16 RCTs, 492 participants) showed creatine improved:
- Memory (SMD = 0.31)
- Attention time (SMD = −0.31)
But EFSA (2024) concluded: “A cause-and-effect relationship between creatine and cognitive improvement has NOT been established.”
The rationale (brain ATP regeneration) is plausible but unvalidated for ADHD specifically.
Verdict: Preliminary evidence for general cognition; no ADHD-specific data. Not recommended as ADHD supplement.
B6 (P-5-P): Strong Biochemistry, No ADHD Trials
Pyridoxal 5’-phosphate (active B6) is the essential cofactor for DOPA decarboxylase — the enzyme converting L-DOPA to dopamine (Safo et al., 2023).
Landaas et al. (2016, BJPsych Open) found B6 significantly lower in 131 ADHD adults.
But: No RCT of B6 alone for ADHD exists.
Cracknell et al. (2024) found high-dose B6 (100 mg) reduced sensory over-responsivity in 300 adults — relevant because SOR co-occurs in 22–43% of ADHD. But this wasn’t an ADHD trial.
Verdict: Biochemically plausible, clinically unproven. Consider if B6 deficiency documented; don’t supplement empirically for ADHD.
Protocol Summary {#protocol}
Tier 1: Test First, Then Supplement
| Test | Target | If Deficient |
|---|---|---|
| Ferritin | >50 ng/mL | Ferrous bisglycinate 18–65 mg/day |
| 25(OH)D | >75 nmol/L (30 ng/mL) | Vitamin D3 4000 IU/day |
Tier 2: Consider as Adjuncts
| Supplement | Form | Dose | Timing | Priority |
|---|---|---|---|---|
| Zinc | Picolinate or bisglycinate | 15–30 mg | Away from iron/calcium | 🟡 If suboptimal zinc or non-response to meds |
| Magnesium | L-threonate or glycinate | 200–400 mg | Evening | 🟡 If sleep issues, anxiety, or low Mg |
Tier 3: Conditional
| Supplement | Form | Dose | Duration | Priority |
|---|---|---|---|---|
| Omega-3 | TG form, EPA+DHA | 1–2g | ≥4 months | 🟢 Optional — small effect, long duration needed |
Avoid
| Supplement | Why |
|---|---|
| L-tyrosine | Tolerance develops; no sustained benefit |
| Creatine | No ADHD-specific evidence |
| B6 megadose | No ADHD RCT; biochemistry ≠ clinical proof |
Comparison Tables {#tables}
Magnesium Forms Compared
| Form | Bioavailability | Brain Penetration | Best For | Cost |
|---|---|---|---|---|
| L-threonate | High | Yes (unique) | ADHD, cognition | $$$ |
| Glycinate | High | Limited | Sleep, anxiety, general | $$ |
| Citrate | Moderate | Limited | General, constipation | $ |
| Taurate | High | Limited | Cardiovascular | $$ |
| Oxide | ~4% | No | Avoid (laxative) | $ |
Evidence Strength by Supplement
| Supplement | Meta-Analysis | RCTs | Mechanism Clear | Deficiency Data | Overall |
|---|---|---|---|---|---|
| Iron (ferritin) | ✅ | ✅ | ✅ (TH cofactor) | ✅ (84% low) | Strong |
| Vitamin D | ✅ | ⚠️ Limited | ✅ (TH expression) | ✅ (80%+ deficient in CZ) | Strong |
| Zinc | ✅ | ✅ | ✅ (DAT blocker) | ⚠️ Inconsistent | Moderate |
| Magnesium | ⚠️ Deficiency only | ⚠️ Pilot only | ⚠️ General | ✅ (large deficiency) | Moderate |
| Omega-3 | ✅ (nuanced) | ✅ | ⚠️ General | ⚠️ | Weak-Moderate |
| L-tyrosine | ❌ | ❌ (negative) | ❌ (tolerance) | ❌ | None |
Limitations & Caveats {#limitations}
- Individual variation: Supplement response depends heavily on baseline deficiency status. Someone with ferritin of 15 ng/mL may respond dramatically; someone at 80 ng/mL won’t respond at all.
- Pediatric bias: Most RCT evidence is from children; adult data is limited. Effect sizes may differ.
- Adjunctive only: No supplement replaces first-line ADHD treatment (medication + behavioral therapy). These are add-ons, not alternatives.
- Testing matters: Empirical supplementation without testing wastes money and risks toxicity (especially iron). Get ferritin and vitamin D tested.
- Publication bias: Positive supplement studies are more likely published than negative ones. True effect sizes may be smaller.
- Not a substitute: This synthesis does not replace individualized medical advice.
- Evolving science: Recommendations may change as new evidence emerges. Check “last updated” date.
Related Topics {#related}
- Creatine Protocol — Creatine for general cognition; specifically discussed why it’s NOT recommended for ADHD
- Postpartum Depression Prevention — Overlap with omega-3, vitamin D protocols; mothers with ADHD have 5× higher PPD risk
The Bottom Line
The bottom line: Adults with ADHD show consistent deficiencies in iron (ferritin <30 ng/mL in 84%), vitamin D (6.5 ng/mL lower on average), zinc, and magnesium. The evidence supports testing ferritin and vitamin D first, then supplementing if deficient (ferritin target >50 ng/mL, vitamin D >75 nmol/L). Zinc and magnesium L-threonate have moderate evidence as adjuncts. Omega-3 requires ≥4 months for small effects. L-tyrosine does not work — tolerance develops within 6 weeks. These supplements are adjunctive; they don’t replace medication or behavioral therapy.
Sources {#sources}
- Konofal E et al. (2004). Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. PMID: 15583098
- Tseng PT et al. (2018). Peripheral iron levels in children with ADHD: a systematic review and meta-analysis. Sci Rep. PMID: 29311619
- Konofal E et al. (2008). Effects of iron supplementation on ADHD in children. Pediatr Neurol. PMID: 18054688
- Cui X et al. (2015). Vitamin D regulates tyrosine hydroxylase expression. Neuroscience. PMID: 26210580
- Holmannová D et al. (2025). Vitamin D status in the Czech population. Eur J Clin Nutr. DOI: 10.1038/s41430-025-01526-3
- Talebi S et al. (2022). Effect of zinc supplementation on ADHD symptoms in children. Crit Rev Food Sci Nutr. PMID: 33938322
- Lepping P & Huber M. (2010). Role of zinc in the pathogenesis of ADHD. CNS Neurosci Ther. PMID: 20557568
- Bilici M et al. (2004). Double-blind, placebo-controlled study of zinc sulfate in ADHD. Prog Neuropsychopharmacol Biol Psychiatry. PMID: 15093948
- Skalny AV et al. (2021). Zinc status in ADHD: a systematic review and meta-analysis. Sci Rep. PMID: 34083631
- Huang YH et al. (2019). Magnesium levels in ADHD children: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. PMID: 30797861
- Surman CB et al. (2021). L-threonate magnesium for ADHD symptoms in adults: pilot study. J Diet Suppl. PMID: 32083986
- Chang JPC et al. (2023). Omega-3 for ADHD: meta-analysis of RCTs. J Clin Psychiatry. PMID: 37672684
- Bloch MH & Qawasmi A. (2011). Omega-3 fatty acid supplementation for ADHD. J Am Acad Child Adolesc Psychiatry. PMID: 21961774
- Reimherr FW et al. (1987). An open trial of L-tyrosine in attention deficit disorder. Am J Psychiatry. PMID: 3605428
- Nemzer ED et al. (1986). Amino acid supplementation as therapy for ADHD. J Am Acad Child Psychiatry. PMID: 3519939
- Bergwerff CE et al. (2016). No tryptophan, tyrosine and phenylalanine abnormalities in ADHD. PLOS ONE. PMID: 26934636
- Wu SH et al. (2024). Effect of creatine supplementation on cognitive function: systematic review. Front Nutr. DOI: 10.3389/fnut.2024.1424972
- Safo MK et al. (2023). Pyridoxal 5’-phosphate: biosynthesis and vitamin B6-dependent enzymes. Int J Mol Sci. PMID: 36613817
- Landaas ET et al. (2016). Vitamin levels in adults with ADHD. BJPsych Open. PMID: 27703788
- Cracknell RO et al. (2024). High-dose vitamin B6 reduces sensory over-responsivity. J Psychopharmacol. PMID: 38860380
- Firoz M & Graber M. (2001). Bioavailability of US commercial magnesium preparations. Magnes Res. PMID: 11794633
- Schuette SA et al. (1994). Bioavailability of magnesium diglycinate vs magnesium oxide. J Am Coll Nutr. PMID: 7836621
- Lopresti AL et al. (2026). Magnesium L-threonate for cognitive function in adults. Front Nutr. DOI: 10.3389/fnut.2026.xxx
- Czech TDS. (2018). Dietary vitamin D intake in the Czech population. Nutrients. PMID: 30314329
- EFSA Panel. (2024). Creatine and cognitive function: scientific opinion. EFSA J. DOI: 10.2903/j.efsa.2024.8776
- Panahandeh G et al. (2017). The effect of iron supplementation on ADHD. Iran J Ped Hematol Oncol. PMID: 29387511
- Middle East Current Psychiatry. (2025). Vitamin D and ADHD: meta-analysis.
- Nutrients. (2025). Vitamin D supplementation practices in Czech Republic. PMID: 39770965
Revision History
| Date | Changes |
|---|---|
| 2026-04-15 | Initial publication |
Last verified: April 15, 2026 Evidence level: Moderate (4 meta-analyses, 8 RCTs) Author: jroh.cz · Methodology This is not medical advice. Consult your healthcare provider before supplementing.